RxDoctor Payments Data

Thomas Degrave, DO

Family Medicine · Orchard Park, NYNPI 1134187537

Payments from drug & device makers

$620in general payments, 2019–2025

Across 36 payments — averaging $17.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$113
  • Novo Nordisk$95
  • Lilly USA, LLC$62
  • GSK$62
  • AbbVie$56
  • Pfizer$37
  • plus $195 from 9 others

What the payments were for

  • Food & beverage$620100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$620 in reported general payments places this provider in the 55th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$51,743
Medicare patients
154
Services billed
622

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban164$155,087
JardianceEmpagliflozin103$154,234
OzempicSemaglutide63$64,161
Trelegy ElliptaFluticasone/Umeclidin/Vilanter83$60,308
TrulicityDulaglutide31$52,655
RybelsusSemaglutide18$51,043
ProliaDenosumab26$43,911
XifaxanRifaximin12$41,181
FarxigaDapagliflozin Propanediol24$38,687
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog28$33,057
XareltoRivaroxaban28$29,390
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr35$20,186
Atorvastatin Calcium584$10,240
Breo ElliptaFluticasone/Vilanterol26$10,057
Rosuvastatin Calcium473$8,664

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$37$155,087164 claims
Novo NordiskOzempic, Rybelsus$95$115,20481 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta, Shingrix$62$102,199182 claims
Lilly USA, LLCTrulicity$62$52,65531 claims
AstraZenecaFarxiga$24$38,68724 claims
Johnson & JohnsonXarelto$13$29,39028 claims
AbbVieSynthroid$56$3,90547 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 4,321 family medicine providers in New York.

Other family medicine in Orchard Park

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →